Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 9/20 | 0.96 |
| ▸ | GNAI3 | P08754 | 8/20 | 0.96 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.96 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | EBP | Q15125 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | GUSB | P08236 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4249763 | 1.00 | GNAO1 (0.96) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL19779489 | 1.00 | GNAO1 (0.96) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL595977 | 0.98 | GNAO1 (0.92) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| Dimethylamine SCHEMBL6943083 | 0.92 | GNAO1 (0.82) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL6941884 | 0.91 | GNAO1 (0.81) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| Hydrochloric Acid SCHEMBL9481013 | 0.89 | GNAO1 (0.85) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| Diethylamine SCHEMBL6941583 | 0.89 | GNAO1 (0.77) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL24261282 | 0.88 | GNAO1 (0.76) | GNAO1GNAI3GNAI1SPHK1BCHE | |
| SCHEMBL22778650 | 0.88 | GNAO1 (0.76) | GNAO1GNAI3GNAI1SPHK1BCHE | |
| SCHEMBL24753537 | 0.88 | GNAO1 (0.76) | GNAO1GNAI3GNAI1SPHK1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210169918-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | SAREPTA THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-10905709-B2 | Modified antisense oligomers for exon inclusion in spinal muscular atrophy | SAREPTA THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10849917-B2 | Antisense-induced exon exclusion in type VII collagen | SAREPTA THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190201425-A1 | ANTISENSE-INDUCED EXON EXCLUSION IN TYPE VII COLLAGEN | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-07-04 | — | — | US | disclosed |
| US-20190015440-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-01-17 | — | — | US | disclosed |
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
| US-9409122-B2 | Gas capture process | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-08-09 | — | — | US | disclosed |
| US-20140127103-A1 | GAS CAPTURE PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2014-05-08 | — | — | US | disclosed |
| US-6989447-B2 | Compounds | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-01-24 | — | — | US | disclosed |
| EP-1121355-B1 | QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-20040116452-A1 | Compounds | SMITHKLINE BEECHAM P.I.C. | 2004-06-17 | — | — | US | disclosed |
| EP-1202987-B1 | QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-11-26 | — | — | EP | disclosed |
| US-6602882-B1 | Quinoline derivatives and their use as antibacterial agents | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-08-05 | — | — | US | disclosed |
| EP-1202987-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2002-05-08 | — | — | EP | disclosed |
| EP-1121355-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2001-08-08 | — | — | EP | disclosed |
| WO-2001007433-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-02-01 | — | — | WO | disclosed |
| WO-2000021952-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | GNAO1 897/4885GNAI3 572/4885GNAI1 596/4885 |
| US-20190015440-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | SMN1; SMN2, UPF1, RBM17 | GNAO1 1973/4885GNAI3 2328/4885GNAI1 2612/4885 |
| US-10905709-B2 | Modified antisense oligomers for exon inclusion in spinal muscular atrophy | SMN1; SMN2, UPF1, RBM17 | GNAO1 1973/4885GNAI3 2328/4885GNAI1 2612/4885 |
| US-10849917-B2 | Antisense-induced exon exclusion in type VII collagen | COL2A1, COL14A1, COL1A1 | GNAO1 3327/4885GNAI3 3431/4885GNAI1 3587/4885 |
| US-20190201425-A1 | ANTISENSE-INDUCED EXON EXCLUSION IN TYPE VII COLLAGEN | COL2A1, COL14A1, COL1A1 | GNAO1 3327/4885GNAI3 3431/4885GNAI1 3587/4885 |
| US-20210169918-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | SMN1; SMN2, UPF1, RBM17 | GNAO1 1973/4885GNAI3 2328/4885GNAI1 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.